NextFerm Technologies now commercially producing its vegan protein, ProteVin
NextFerm Technologies has announced the end of its commissioning period of the commercial facility in Canada and first commercial production of its vegan protein, ProteVin.
Photo © AdobeStock.com/ New Africa
NextFerm Technologies Ltd. (YokneamIllit, Israel) met its first milestone out of the five it set for 2022: the end of its commissioning period of the commercial facility in Canada and first commercial production of its vegan protein, ProteVin.
“Initiating commercial production of ProteVin, marks a significant milestone for the company moving forward from R&D phase to commercial phase,” said Boaz Noy, CEO of NextFerm, in a press release. “Achieving this milestone allows us to progress towards achieving the additional milestones we set for 2022. In the coming weeks, we expect to supply first orders of ProteVin for customers in the field of sports-nutrition formulas.”
NextFerm continues to work on its other objectives, including delivery of initial orders received, increasing market demand for ProteVin, receipt of additional purchase orders, and expanding penetration into the global food market.
Magnesium L-threonate, Magtein, earns novel food authorization in the European Union
December 19th 2024According to the announcement, the authorization is also exclusive to AIDP and its partner company and licensee, ThreoTech, meaning that they are the only parties that can market magnesium L-threonate in the EU for a period of five years.
